Leprosy reactions are acute immune-mediated inflammatory episodes that complicate the course of Mycobacterium leprae infection and represent the major cause of nerve damage and disability in leprosy. [1-2] Three types are recognized: Type 1 (reversal reaction), Type 2 (erythema nodosum leprosum/ENL), and Lucio's phenomenon. [1-2] Reactions may occur before, during, or years after successful antimicrobial therapy. [1][3]
1. History
- Timing relative to MDT: Reactions often occur soon after starting chemotherapy (Type 1) or within the first year of treatment (~50% of lepromatous patients develop ENL in year one) [1][4]
- Onset pattern: Type 1 — acute/subacute worsening of existing skin lesions and nerve pain; Type 2 — abrupt onset of fever, crops of new painful nodules, systemic symptoms [1]
- Symptom characterization:
- Type 1: Existing lesions become erythematous, edematous, painful; new lesions may appear; facial/hand edema; nerve tenderness with motor/sensory loss [1]
- Type 2 (ENL): Fever, arthralgia, dactylitis, painful erythematous nodules (face, extensor surfaces), malaise; may include orchitis, eye pain, epistaxis, depression [1][4]
- Lucio's: Painful skin necrosis in a net-like (retiform) pattern on previously cyanotic areas [1]
- Triggers: Initiation of MDT, pregnancy/postpartum (puerperium), lactation, puberty, intercurrent infections, emotional stress [1][5]
- Important negatives: Ask about visual changes (iridocyclitis), testicular pain (orchitis), joint swelling, urinary changes (glomerulonephritis), and prior reaction episodes [1][4]
2. Alarm Features
- Acute neuritis with rapid motor/sensory loss — risk of irreversible paralysis and anaesthesia if treatment is delayed [1-2]
- Iridocyclitis/anterior uveitis — risk of permanent vision loss [1]
- Lucio's phenomenon — life-threatening necrotizing vasculitis with skin necrosis; high mortality from superimposed sepsis [1]
- Ulcerating/pustular ENL nodules — may mimic sepsis or Sweet syndrome [1][6]
- Orchitis — risk of testicular atrophy and infertility [4]
- Glomerulonephritis with albuminuria [1][4]
- Signs of steroid toxicity in patients on prolonged immunosuppression (infections, especially TB reactivation — infections account for 75% of corticosteroid-associated mortality in ENL) [7]
3. Medications
First-line treatment
- Corticosteroids (prednisolone) — first-line for both Type 1 and Type 2 reactions [1][4]
- Longer courses (≥20 weeks) appear superior to shorter courses (12 weeks); ~50% of patients require additional prednisolone beyond 16 weeks [8-9]
- Relapse rate after steroid therapy: 20–50% [8]
Type 1 reaction steroid-sparing agents: Azathioprine, methotrexate, cyclosporine [1]
Type 2 (ENL) specific
- Thalidomide — treatment of choice for ENL; FDA-approved dose 100–300 mg/day (up to 400 mg/day for severe cases); taper by 50 mg every 2–4 weeks once symptoms subside [10]
- Absolutely contraindicated in pregnancy (teratogenicity); requires REMS program compliance [10]
- Low-dose regimens (25–150 mg/day) have shown comparable efficacy in real-world studies [6][11]
- Clofazimine — steroid-sparing; superior to thalidomide for preventing ENL recurrence in some trials [12]
- Methotrexate — additional steroid-sparing option [1]
Lucio's phenomenon: Antimicrobials + anti-inflammatory + anticoagulant therapy + wound care; no standardized regimen [1]
Key cautions
- Continue MDT (dapsone, rifampin, clofazimine) during reactions — do not stop [3-4]
- Screen for latent TB and other infections before prolonged immunosuppression [1][7]
- Monitor for dapsone hypersensitivity syndrome (distinct from leprosy reactions)
4. Diet
- No specific dietary triggers for leprosy reactions
- Ensure adequate caloric and protein intake during catabolic inflammatory states
- Calcium and vitamin D supplementation during prolonged corticosteroid use to mitigate osteoporosis (36% of ENL patients on long-term steroids develop osteoporosis) [7][11]
- Monitor for corticosteroid-induced hyperglycemia — dietary counseling for glucose control
5. Review of Systems
- Skin: New or worsening lesions, nodules, ulceration, skin necrosis (retiform purpura)
- Neurologic: Numbness, tingling, weakness, claw hand, foot drop, nerve tenderness
- Ophthalmologic: Eye pain, redness, photophobia, blurred vision (iridocyclitis)
- Musculoskeletal: Joint pain/swelling, dactylitis
- Genitourinary: Testicular pain/swelling (orchitis), foamy urine (proteinuria)
- Constitutional: Fever, malaise, weight loss, depression [1][4]
- ENT: Epistaxis, nasal congestion [1][4]
6. Collateral History and Family History
- Household contacts with leprosy — important for epidemiologic context
- Country of origin/travel to endemic areas (South/Southeast Asia, Brazil, sub-Saharan Africa; Lucio's phenomenon predominantly in Central/South America) [1]
- HIV status — coinfection increases risk of ENL (RR 5.2) and recurrent reversal reactions (RR 2.7) [5]
- Pregnancy/postpartum status — hormonal shifts predispose to both Type 1 and Type 2 reactions [1]
- Prior reaction episodes — chronicity and recurrence are common (55% of ENL patients have >2 episodes) [13]
7. Risk Factors
- Type 1 reaction: Borderline-borderline classification, positive skin-slit smears, anti-PGL-I seropositivity, male sex, age >15 years, puerperium [1]
- Type 2 (ENL): Lepromatous or borderline lepromatous classification, bacteriologic index ≥4, pregnancy/lactation/puberty [1]
- Both types: Initiation of MDT, multibacillary disease (~30% of MB patients develop reactions) [8]
- HIV coinfection increases reaction frequency [5]
- Patients with BI <4 who develop ENL have a 37% higher incidence of recovery compared to higher BI [14]
8. Differential Diagnosis
ENL mimics (frequently misdiagnosed): [1]
- Systemic lupus erythematosus — fever, arthritis, skin nodules, glomerulonephritis overlap
- Rheumatoid arthritis — joint involvement, dactylitis
- Vasculitis (e.g., polyarteritis nodosa) — skin nodules, systemic inflammation
- Sarcoidosis — granulomatous skin lesions, lymphadenopathy
- Lymphoma — nodules, lymphadenopathy, constitutional symptoms
- Sweet syndrome — pustular/vesicular ENL can closely mimic [6]
Type 1 reaction mimics
- Mycosis fungoides — epidermotropism can be seen in reversal reactions [1]
- CIDP — leprosy neuropathy fulfills CIDP criteria in >93% of demyelinating cases; a critical misdiagnosis in non-endemic areas [15]
- Drug reaction (dapsone hypersensitivity syndrome)
Lucio's phenomenon mimics
- Calciphylaxiswarfarin necrosisDICantiphospholipid syndrome
9. Past Medical History
- Leprosy classification (Ridley-Jopling or WHO PB/MB) — determines reaction risk
- Prior reaction episodes and treatments used (steroid dependence is common)
- Duration of MDT and completion status
- Bacteriologic index at diagnosis
- Prior steroid-related complications: Cushingoid habitus (82%), weight gain (55%), osteoporosis (36%), cataracts (18%), diabetes (9%) [7][11]
- Latent TB status — critical before immunosuppression
- Pregnancy history in women of childbearing age (thalidomide contraindication)
10. Physical Exam
- Skin: Inflamed, erythematous, edematous pre-existing lesions (Type 1); crops of tender erythematous nodules on face/extensor surfaces that may ulcerate or become pustular (ENL); retiform purpura/necrosis on cyanotic areas (Lucio's) [1]
- Nerves: Palpate ulnar, radial, common peroneal, posterior tibial nerves for thickening and tenderness; assess for nerve abscess [1]
- Motor: Test grip strength, finger abduction (ulnar), wrist/finger extension (radial), dorsiflexion (peroneal) — document baseline and serial changes
- Sensory: Monofilament testing of hands and feet; map areas of hypoesthesia/anesthesia
- Eyes: Slit-lamp exam for iridocyclitis; assess for lagophthalmos, corneal sensation [1]
- Testes: Tenderness/swelling (orchitis in ENL) [4]
- Lymph nodes: Lymphadenopathy (ENL) [1]
- Vitals: Fever (common in ENL; generally absent in Type 1); tachycardia
11. Lab Studies
- CBC with differential: Neutrophilic leukocytosis correlates with ENL severity (median neutrophils 6,066 cells/mm³ in mild vs. 10,243 in moderate/severe ENL) [13]
- ESR/CRP: Elevated during reactions (nonspecific but useful for monitoring)
- Urinalysis: Proteinuria/albuminuria (glomerulonephritis in ENL) [4]
- Renal function (BMP): Assess for glomerulonephritis
- Liver function tests: Baseline before immunosuppressive therapy
- Fasting glucose/HbA1c: Steroid-induced diabetes monitoring [7]
- Slit-skin smear/bacteriologic index: Helps classify disease and predict reaction risk [1]
- Skin biopsy: Type 1 — lymphocytic infiltrate with granulomas and dermal edema; ENL — neutrophilic infiltration of granulomas (hallmark in lesions <24–72 hours) with vasculitis [1]
- TB screening (PPD/IGRA, chest X-ray) before prolonged steroid use [1]
- Pregnancy test before thalidomide initiation [10]
- No reliable serologic biomarker currently exists to predict or diagnose reactions [16]
12. Imaging
- Neuromuscular ultrasound: Useful for assessing nerve thickening, edema, and guiding perineural steroid injections [17]
- Nerve conduction studies (NCS/EMG): Demonstrates demyelinating and/or axonal patterns; conduction block and temporal dispersion are common during reactions [15]
- Chest X-ray: Prior to prolonged immunosuppression (TB screening)
- MRI of affected nerves: Can demonstrate nerve enlargement and inflammation in equivocal cases
- Routine imaging is generally unnecessary for straightforward reaction diagnosis (clinical diagnosis is standard) [1]
13. Special Tests
- Voluntary muscle testing (VMT) and sensory testing (ST): Serial nerve function assessments are the cornerstone of monitoring — document at every visit [18]
- Monofilament testing: Semmes-Weinstein monofilaments for graded sensory assessment
- Slit-skin smear: Bacteriologic index helps stratify reaction risk
- Skin biopsy with S-100 immunostain: Quantifies nerve fiber destruction; greater fragmentation in Type 2 vs. Type 1 reactions [19]
- Reaction Severity Score (RSS): Used in research settings to grade ENL severity [20]
- Visual Analog Scale (VAS): For pain assessment and treatment response monitoring [20]
14. ECG
- Not routinely indicated for leprosy reactions
- Consider ECG if using clofazimine (rare reports of QT prolongation at high doses)
- Baseline ECG if considering thalidomide (rare cardiac events reported)
- Standard indications apply for patients with fever and systemic illness
15. Assessment
Three reaction types with distinct pathophysiology
Key clinical pearl: Reactions can occur years after completing MDT and may be the initial presentation of previously undiagnosed leprosy. [1-2] In non-endemic areas, ENL is frequently misdiagnosed as SLE, vasculitis, or lymphoma. [1]
16. Treatment Plan
Type 1 (Reversal) Reaction
- Prednisolone 40–60 mg/day (or ~1 mg/kg/day), tapered over ≥20 weeks (longer courses superior to 12 weeks) [8][21]
- If neuritis present: high-dose steroids are mandatory; consider hospitalization [4]
- Steroid-sparing agents for refractory/chronic cases: azathioprine, methotrexate, or cyclosporine [1]
- Surgical decompression of swollen nerve trunks if medical therapy fails [4][21]
Type 2 (ENL)
- Mild: NSAIDs ± low-dose prednisolone
- Moderate-severe: Thalidomide 100–300 mg/day (up to 400 mg/day); taper by 50 mg every 2–4 weeks after symptom control [10]
- Add corticosteroids if neuritis is present [10]
- Low-dose thalidomide (25–150 mg/day) may be effective and more affordable [11]
- Chronic/recurrent ENL: Clofazimine 300 mg/day (superior for preventing recurrence); methotrexate as steroid-sparing agent [1][12]
- Thalidomide REMS: Mandatory pregnancy prevention program; contraindicated in women of childbearing potential unless strict contraception [10]
Lucio's Phenomenon
- Antimicrobial therapy for bacterial clearance
- Anti-inflammatory agents + anticoagulation
- Supportive wound care
- No standardized protocol exists [1]
For all reactions: Continue MDT — do not discontinue anti-leprosy treatment [3-4]
17. Disposition
Admission criteria
- Severe neuritis with acute motor/sensory loss [4]
- Severe ENL with ulcerating/pustular lesions, high fever, or organ involvement (orchitis, iridocyclitis, glomerulonephritis) [4]
- Lucio's phenomenon (high mortality risk) [1]
- Need for IV methylprednisolone [9]
- Inability to manage oral medications or ensure follow-up
Discharge/outpatient criteria
- Mild Type 1 reaction without neuritis
- Mild ENL with skin-only involvement and low-grade fever [12]
- Stable on oral prednisolone or thalidomide with reliable follow-up
Specialist consultation triggers
- Contact the National Hansen's Disease Program (NHDP, formerly USPHS Carville) for management guidance in the United States [4]
- Ophthalmology for iridocyclitis/eye involvement
- Neurology/hand surgery for progressive nerve function loss or consideration of decompressive surgery [21]
- Infectious disease for complex or refractory cases
18. Follow Up / Return Precautions
- Serial nerve function testing (VMT/ST) at every visit — the earlier corticosteroids are given after onset of nerve damage, the more likely permanent impairment will be prevented [18][21]
- Follow-up frequency: Monthly during active reaction; more frequently if on steroid taper (50% require additional prednisolone) [9]
- Monitor for steroid complications: Glucose, blood pressure, bone density, cataracts, weight, infection screening [7]
- Reactions can recur for years after MDT completion — patients must be counseled to return for any new skin lesions, nerve pain, weakness, numbness, or eye symptoms [1][8]
- Return precautions:
- New weakness or numbness in hands/feet
- Eye pain, redness, or vision changes
- Fever with new skin nodules
- Skin necrosis or ulceration
- Testicular pain/swelling
- Expected course: Type 1 reactions typically resolve over weeks to months with treatment; ENL may be chronic/recurrent over years; disability burden may manifest decades later [1][8]
References
1. Leprosy. — Agudelo Higuita NI, Avanzi C, Henao-Martínez AF, et al. Lancet. 2026.
2. Recognizing and Managing the Immunologic Reactions in Leprosy. — Kamath S, Vaccaro SA, Rea TH, Ochoa MT. Journal of the American Academy of Dermatology. 2014.
3. Hansen's Disease (Leprosy): Current and Future Pharmacotherapy and Treatment of Disease-Related Immunologic Reactions. — Legendre DP, Muzny CA, Swiatlo E. Pharmacotherapy. 2012.
4. FDA Drug Label. — Updated date: 2026-02-27. Food and Drug Administration.
5. Interactions Between HIV Infection and Leprosy: A Paradox. — Ustianowski AP, Lawn SD, Lockwood DN. The Lancet. Infectious Diseases. 2006.
6. Case Report: Rapid Response to Low-Dose Thalidomide in a Case of Severe Steroid Recalcitrant Erythema Nodosum Leprosum. — Savitha B, Sardana K, Kumari R, et al. The American Journal of Tropical Medicine and Hygiene. 2021.
7. A Systematic Review of Adverse Effects Associated With Systemic Corticosteroids in the Management of Leprosy. — Lun AI, de Barros B, Walker SL. PLoS Neglected Tropical Diseases. 2026.
8. Leprosy Now: Epidemiology, Progress, Challenges, and Research Gaps. — Rodrigues LC, Lockwood DNj. The Lancet. Infectious Diseases. 2011.
9. A Phase Two Randomised Controlled Double Blind Trial of High Dose Intravenous Methylprednisolone and Oral Prednisolone Versus Intravenous Normal Saline and Oral Prednisolone in Individuals With Leprosy Type 1 Reactions and/or Nerve Function Impairment. — Walker SL, Nicholls PG, Dhakal S, et al. PLoS Neglected Tropical Diseases. 2011.
10. FDA Drug Label. — Updated date: 2023-03-24. Food and Drug Administration.
11. A Real-World Study of Low-Dose Thalidomide in Severe Erythema Nodosum Leprosum Highlighting Its Mechanistic Rationale in a Resource-Constrained Target Population. — Bathula S, Sardana K, Mathachan SR, et al. International Journal of Dermatology. 2023.
12. Interventions for Erythema Nodosum Leprosum. — Van Veen NH, Lockwood DN, van Brakel WH, Ramirez J, Richardus JH. The Cochrane Database of Systematic Reviews. 2009.
13. Neutrophilic Leukocytosis and Erythema Nodosum Leprosum in Leprosy: Insights From a Retrospective Observational Study. — Feitosa da Silva Barboza M, de Andrea Hacker M, Maria Sales A, et al. Frontiers in Immunology. 2024.
14. Thalidomide in the Treatment of Erythema Nodosum Leprosum (ENL) in an Outpatient Setting: A Five-Year Retrospective Analysis From a Leprosy Referral Centre in India. — Upputuri B, Pallapati MS, Tarwater P, Srikantam A. PLoS Neglected Tropical Diseases. 2020.
15. Leprosy Neuropathy and Demyelinating Impairment: How Should We Interpret This Neurophysiological Pattern?. — Dos Santos DF, Carvalho IR, Borges IS, et al. PloS One. 2025.
16. Host-Related Laboratory Parameters for Leprosy Reactions. — Luo Y, Kiriya M, Tanigawa K, et al. Frontiers in Medicine. 2021.
17. Case Report: Injected Corticosteroids for Treating Leprosy Isolated Neuritis. — Spitz CN, Pitta IJR, Andrade LR, et al. Frontiers in Medicine. 2023.
18. Treatment and Evaluation Advances in Leprosy Neuropathy. — Ebenezer GJ, Scollard DM. Neurotherapeutics : The Journal of the American Society for Experimental NeuroTherapeutics. 2021.
19. Study of Dermal Nerve Pathology in Upgrading and Downgrading Type 1 and Type 2 Leprosy Reactions. — Sharath S, Ahuja A, Sinha S, Sardana K. The American Journal of Tropical Medicine and Hygiene. 2025.
20. Thalidomide and Steroid in the Management of Erythema Nodosum Leprosum. — P K Mishra SR, Samal R, Behera B. Indian Journal of Pharmacology. 2022.
21. Decompressive Surgery for Treating Nerve Damage in Leprosy. — Van Veen NH, Schreuders TA, Theuvenet WJ, Agrawal A, Richardus JH. The Cochrane Database of Systematic Reviews. 2012.